AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patients

In two late-stage studies, an AstraZeneca therapy showed a statistically significant reduction in acute exacerbations that worsen chronic obstructive pulmonary disease. The data, released on Tuesday, indicated the drug lowered the frequency of these dangerous flare-ups compared with standard care.

The findings suggest the medicine could become a valuable addition to the limited treatment arsenal for COPD, a condition that affects millions worldwide and carries a high burden of morbidity.

If the results are confirmed in further regulatory review, patients may soon have access to a new therapeutic option that could improve quality of life and reduce hospitalizations associated with severe COPD episodes.